Across TCGA pan-cancer cohorts, LINC01644 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LINC01644 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher LINC01644 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC01644 expression acts as an unfavorable survival marker.
COAD are the cancer types where LINC01644 Mutation most reproducibly stratifies survival.